IP Library Granted Patent US 7,125,890
Granted Patent B2
US 7,125,890 · App. 10/916,125 · Granted Oct 24, 2006

Ether substituted imidazopyridines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,125,890
App. No.
10/916,125
Granted
Oct 24, 2006
Kind
B2
Abstract

Imidazopyridine compounds that contain an ether or thioether functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases. Methods of preparing the compounds and intermediates useful in the preparation of the compounds are also disclosed.

Claims (53)

1. A compound of the formula (I-6):

wherein:

X is —CH(R 5 )—, —CH(R 5 )-alkylene-, —CH(R 5 )-alkenylene-, or CH(R 5 )-alkylene-Y-alkylene-;

R 1-6 is selected from the group consisting of:

-alkyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkenyl;

-R 6 -aryl;

-R 6 -heteroaryl;

-R 6 -heterocyclyl;

R 2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkylene-Y-alkyl;

-alkylene-Y-alkenyl;

-alkylene-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

—OH;

-halogen;

N(R 5 ) 2 ;

—C(O)—C 1-10 alkyl;

—C(O)—O—C 1-10 alkyl;

—N 3 ;

-aryl;

-heteroaryl;

-heterocyclyl;

—C(O)-aryl; and

—C(O)-heteroaryl;

Y is —O— or —S(O) 0-2 —;

R 3 and R 4 are independently selected from the group consisting of hydrogen, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 1-10 alkoxy, C 1-10 alkylthio, amino, alkylamino, dialkylamino, halogen, and nitro;

each R 5 is independently hydrogen, C 1-10 alkyl, or C 2-10 alkenyl; and

R 6 is alkylene, alkenylene, or alkynylene, which may be interrupted by one or more —O— atoms;

or a pharmaceutically acceptable salt thereof.

2. A compound or salt of claim 1 wherein —S(O) 0-2 — is —S—.

3. A compound or salt of claim 1 wherein —S(O) 0-2 — is —SO—.

4. A compound or salt of claim 1 wherein —S(O) 0-2 — is —S(O) 2 —.

5. A compound or salt of claim 1 wherein R 3 and R 4 are independently hydrogen, alkyl, halogen, or nitro.

6. A compound or salt of claim 1 wherein R 3 and R 4 are both methyl.

7. A compound or salt of claim 1 wherein R 2 is hydrogen.

8. A compound or salt of claim 1 wherein R 2 is -alkyl.

9. A compound or salt of claim 1 wherein R 2 is -alkylene-O-alkyl.

10. A compound or salt of claim 1 wherein R 1-6 is alkyl.

11. A compound or salt of claim 1 wherein R 1-6 is aryl.

12. A compound or salt of claim 1 wherein R 1-6 is substituted aryl.

13. A compound or salt of claim 1 wherein R 1-6 is heteroaryl.

14. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1 in combination with a pharmaceutically acceptable carrier.

15. A method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound of claim 1 to the animal wherein the cytokine is interferon α and/or tumor necrosis factor α.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2011
From: COLEY PHARMACEUTICAL GROUP, INC.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 026732/0337 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 19, 2007
From: 3M INNOVATIVE PROPERTIES COMPANY
To: COLEY PHARMACEUTICAL GROUP, INC.
Reel/Frame 019991/0581 →